FLC
OCUL icon

Fifth Lane Capital’s Ocular Therapeutix OCUL Stock Holding History

Fifth Lane Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,358
Closed -$174K – 101
2025
Q4 		$174K Sell
14,358
-2,642
-16% -$32.1K 0.13% 84
2025
Q3 		$199K Buy
+17,000
New +$203K 0.2% 73

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fifth Lane Capital's OCUL Position: Q1 2026 in Review

Fifth Lane Capital sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 14,358 shares — an estimated $174K sold.

Fifth Lane Capital first reported a position in OCUL in Q3 2025 and held it in 2 quarters. The position peaked at $199K in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Fifth Lane Capital reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Fifth Lane Capital sold 14,358 Ocular Therapeutix shares in Q1 2026, an estimated $174K.
  • Fifth Lane Capital first reported a position in Ocular Therapeutix in Q3 2025 and held it in 2 quarters.
  • Fifth Lane Capital's Ocular Therapeutix position peaked at $199K in Q3 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Fifth Lane Capital's 13F filing for Q1 2026, filed 15 May 2026.